Genflow Biosciences Ltd

Genflow Biosciences is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs, supporting longer, healthier lives.  The company's lead compound, GF-1002 operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.